background viiv patent
pivot year littl discuss lawsuit
believ gilead like prevail heighten investor focu
potenti downsid risk could impact stock
provid background lawsuit key upcom date
potenti impact key parti
day fda approv gilead biktarvi viiv healthcar shionogi viiv
su gilead biktarvi allegedli infring composition-of-matt patent
direct hiv integras inhibitor although viiv seek remov biktarvi
market injunct viiv seek financi redress
potenti worth billion provid background patent infring
lawsuit potenti impact parti
disput viiv hiv subsidiari gsk assert composition-of-matt
patent patent biktarvi viiv admit liter
cover gilead bictegravir viiv reli legal rule call doctrin
equival court expand scope claim cover bictegravir
doctrin equival allegedli infring product need
liter cover patent claim accus product patent
product substanti differ gilead file pre-
trial motion argu viiv bar assert doctrin equival
decis motion favor gilead would like resolv disput
entir although think gilead like lose motion
think good chanc prevail trial among
reason viiv shoulder burden show doctrin
equival gilead biktarvi insubstanti differ patent
compound burden particularli heavi sinc feder circuit
recent suggest doctrin regularli avail extend
protect beyond scope claim
potenti impact lawsuit viiv request court take
biktarvi market injunct instead viiv seek damag
viiv form joint-ventur gsk shionogi
describ potenti impact three compani along gilead
gilead impact depend case play gilead could
potenti liabl billion dollar base case estim
calcul could tripl gilead found will
infring patent impli mid-singl digit low doubl digit
potenti downsid also point risk juri could
award unexpectedli high royalti ratese exampl recent
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
note juno kite patent disput yescarta
shionogi impact estim shionogi share cumul
royalti could viiv win shionogi share price would
like rise gilead prevail shionogi share price would like stay
flat fall
gsk impact victori viiv could add gsk
equiti valuat mid-point would gsk
impact impact would immateri given potenti
cumul royalti less quarter percent market cap
time judg connolli district delawar heard oral argument
gilead motion would expect decis first second
quarter year continu monitor report lawsuit
chart recent upcom litig event
litig event delawar
oral hear gilead motion judgment non-infring
plead
expect decis gilead motion judgment non-
juri trial day
morgan stanley research public access court electron record
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
viiv assert patent biktarvi admit disclos liter
cover bictegravir viiv assert patent allegedli direct
novel structur scaffold chemic compound inhibit hiv integras
therefor use anti-hiv agent patent list fda orang book
protect four viiv product contain dolutegravir dovato tivicay triumeq
juluca viiv assert biktarvi infring two claim patent claim
find interest viiv conced patent disclos
bictegravir claim liter encompass bictegravir claim
liter cover bictegravir viiv reli doctrin equival
demonstr biktarvi infring patent
doctrin equival legal rule allow court hold parti liabl
patent infring even though infring product fall within liter
scope patent claim nevertheless equival claim invent
polici behind doctrin prevent someon make minor chang
product avoid infring claim patent thu broaden captur
product minor chang yet polici must balanc
compet polici patent claim provid fair notic infring
outsid scope claim invent
high-level summari argument viiv argu patent claim
broaden doctrin equival captur biktarvi biktarvi
insubstanti differ structur encompass claim contrast
gilead argu biktarvi equival viiv bar seek captur
biktarvi doctrin equivalentsbecaus viiv patent disclos certain
structur featur actual claim captur biktarvi
doctrin equival would violat requir claim must provid fair notic
infring
detail assert claim assert claim claim claim
depend claim reproduc note formula claim refer
dolutegravir
compound accord claim pharmaceut accept salt thereof wherein rx hydrogen hydrogen hydrogen
halogen
compound select group consist
carboxyl acid enantiom thereof diastereom thereof mixtur enantiom thereof mixtur diastereom thereof
mixtur enantiom diastereom thereof pharmaceut accept salt thereof
morgan stanley research unit state patent trademark offic
viiv alleg doctrin equival complaint viiv assert
gilead copi novel structur scaffold develop gsk shionogi team
claim viiv patent use biktarvi thu even though biktarvi
structur patent compound viiv assert biktarvi nevertheless
equival insubstanti differ particular viiv alleg bictegravir
substanti differ patent compound two way
bictegravir bridg ring substanti differ ring
dolutegravir compound claim patent viiv complaint
bictegravir trifluoro benzyl ring substanti differ difluoro
benzyl ring claim viiv complaint
structur bictegravir dolutegravir compound describ
claim exemplari compound disclos claim
exhibit bictegravir compar compound viiv patent
gilead complaint
importantli note awar lawsuit one brand compani
su anoth brand compani patent infring accus product
outsid liter scope claim thu think viiv like tough
time prove infring trial
gilead motion judgment plead
gilead file motion judgment non-infring plead
motion signific success potenti end lawsuit
novemb parti present argument court judg
connolli district delawar review brief parti
transcript hear think court like deni gilead motion yet
think neg decis impact gilead abil ultim
prevail trial present parti argument relev comment court
hear
high-level summari gilead argument
court constru claim viiv conced claim liter
cover gilead bictegravir thu left assert infring via doctrin
equival gilead assert viiv preclud reli doctrin
equival two reason thu gilead seek earli judgment non-
biktarvi infring claim doe disclose-ded
doctrin disclosure-ded bar doctrin equival prevent
patente alleg subject matter disclos claim equival
claim
gilead argument viiv alleg bictegravir three-fluorin benzyl ring
equival two-fluorin benzyl ring compound recit claim
patent patent disclos benzyl ring three fluorin
written descript sens patent explicitli repeatedli identifi
three fluorin altern two fluorin thu bictegravir three-fluorin
benzyl ring equival claim two-fluorin benzyl ring
viiv rebutt gilead disclosure-ded argument fail three reason first
requisit disclosur miss gilead viiv agre patent
disclos bictegravir without disclosur bictegravir
dedic bictegravir public second gilead piecem approach
focus three fluorin atom rather full claim element
dolutegravir contrari preced disclosure-ded doctrin
oper level individu atom within claim molecul third
suprem court feder circuit preced subject matter assert
claim patent dedic public
comment court although court acknowledg gilead
good polici argumentthat pick choos among patent disclosur
come basi alleg infring provid clear notic
public patent scopeth court state gilead uphil battl
came relev case law includ johnson johnston assoc inc
biktarvi infring claim doe specif
doctrin specif exclus second bar doctrin equival
prevent patente captur subject matter exclud inconsist
claim limit issu exampl patente limit claim
compound hydrophob compon use doctrin equival
reach compound hydrophil compon inconsist
gilead argument court claim construct substitut
a-r claim must distinct requir group
distinct accord gilead specif exclud one set atom
doubl duti two posit a-r render
indistinct bictegravir requir distinct substitut fact
indistinct pictur viiv therefor captur
bictegravir doctrin equival
exhibit gilead argument substitut a-r bictegravir indistinct
connect thu inconsist claim requir
gilead open brief
viiv rebutt name specif exclus indic gilead must point
languag patent clearli specif exclud bictegravir
claim ordinarili neg claim limit metal equival
non-metal minor equival major specif
exclus afoot court construct independ
element claim mean distinct exclud equival
bictegravir consist claim distinct claus
court construct simpli indic substitut posit
distinct one anoth court adopt gilead propos construct
requir separ
connect anoth exampl look one molecul
within claim illustr one distinguish green
pink likewis bictegravir illustr one
easili distinguish green pink
viiv also argu decid whether specif exclus appli requir factual
determin inappropri judgment plead
pure legal inquiri
exhibit viiv argument substitut bictegravir meet claim requir
viiv respons brief
comment court three observ judg connolli question
stand first judg connolli character determin whether bridg ring
bictegravir constitut distinct substitut posit involv
metaphys reflect abstrus issu second end oral
argument judg connolli ask whether court use specific-exclus
doctrin bar applic doctrin equival earli stage
case gilead seek gilead conced awar
case third consid issu judg connolli question whether
constru claim correctli suggest may come new
claim construct could potenti resolv disput moot gilead
think court like issu decis gilead lose motion
anticip loss like impact gilead odd win trial
start septemb
viiv abl prove biktarvi infring claim patent gilead unabl
prove claim invalid issu appropri remedi viiv aris viiv
request court take biktarvi market injunct instead
viiv seek financi redress financi redress could come two form
royalti base sale biktarvi lost profit essenti profit lost
viiv due sale biktarvi occur place sale viiv product viiv
seek enhanc damag much three-fold demonstr
gilead will infring patent told depend case play
gilead could potenti liabl billion dollar base expect sale
biktarvi reason royalti rate gilead could owe could
tripl gilead found will infring patent
common framework determin reason royalti patent case
set forth semin case georgia-pacif corp unit state plywood corp
case court enumer multipl factor held relev determin
reason royalti award infring action georgia-pacif advoc use
hypothet negoti framework approxim reason royalti
framework ask much person would will pay use patent-in-suit
hypothet negoti patente infring time
infring presum parti know everyth side know implicit
exercis fact license must still abl make reason profit
use patent
consider determin reason royalti
royalti base viiv alleg hiv integras inhibitor patent cover gilead
bictegravir viiv alleg patent cover two drug
compris three-drug combin biktarvi emtricitabin ftc tenofovir
alafenamid taf accordingli gilead reason claim entir gross
sale biktarvi constitut appropri base reason
royalti instead reason royalti requir apportion ensur
reason royalti base valu patent technolog
non-infring featur includ ftc taf apportion requir
whenev claim featur defin entireti commerci
fed result bictegravir one three
compon biktarvi royalti base lower entir gross
sale biktarvi
valu patent technolog viiv patent composition-of-matt patent
oppos patent direct follow-on technolog formul
dose regimen weigh favor higher royalti rate
commerci relationship parti time hypothet
negoti parti would highli competit relationship
would anticip continu direct competit futur viiv
would expect grant gilead licens would result direct harm
impact sale hiv franchis thu factor weigh favor higher
compar licens factor fact finder consid royalti
rate compar licens agreement enter parti involv hiv
non-infring altern gilead demonstr altern hiv integras
inhibitor equival superior perform claim technolog
dolutegravir allegedli infring bictegravir infring
patent would put signific downward pressur reason royalti
royalti rate estim consider mani factor
depend fact specif case said review propos
reason royalti rate biotech pharmaceut case involv
composition-of-matt patent ballpark royalti rate could
royalti base estim model estim cumul sale biktarvi
year biktarvi approv date patent expir
amount base discuss royalti base lower
bictegravir compris one three compon biktarvi one
compon biktarvi infring viiv patent said bictegravir
newest perhap import compon biktarvi discount
royalti base would less straightforward reduct conserv
estim royalti base could
royalti rate appli royalti base would equal
damag owe gilead gilead found will infring explain
damag could tripl equal
patent allow owner exclud competitor market place lost profit
give patente monetari compens would infring
never infring essenti fulfil purpos patent
although gener harder get lost profit sometim much higher amount
damag due reason royalti viiv potenti get lost profit
relat four product protect accord fda orang book
patent-in-suit dovato tivicay triumeq juluca
lost profit gener hard get patente must satisfi four factor
demand patent product absenc accept non-infring substitut
manufactur capabl exploit demand amount profit
patente would made
clarif note biktarvi sale captur lost profit
subject reason royalti viiv enjoy reason royalti
lost profit biktarvi sale
stage case earli tell kind lost profit gilead
enhanc damag due alleg will infring
theori will infring court may increas damag three
time amount damag found find defend will
infring importantli suprem court recent reduc burden proof
court lower burden proof establish will clear
convinc standard preponder evid standard
publicli avail document short detail gilead may will
infring viiv complaint exampl alleg gilead awar viiv
public structur dolutegravir gilead bictegravir
structur similar dolutegravir suggest gilead copi structur scaffold
dolutegravir although assess whether viiv color
will alleg note includ will alleg matter
cours mani biotech patent litig
potenti impact gsk shionogi
viiv hiv subsidiari gsk hold dolutegravir intellectu properti viiv
form joint-ventur gsk shionogi viiv profit split
gsk shionogi gsk make cash payment shionogi gsk
cover mark purcel david rising shionogi shinichiro muraoka
comment impact gsk shionogi impact
immateri given potenti cumul royalti market cap
potenti impact shionogi
royalti would contribut shionogi earn increas equity-method
gain increas dividend accord stake viiv
damag award estim would posit
impact shionogi equity-method gain tax
addit dividend incom would around would sum posit
impact rp equat shionogi market cap
given difficult predict outcom biktarvi patent infring
disput think share price present follow
potenti scenario present gsk/shionogi prevail shionogi share price
could rise unsuccess shionogi share price like stay put
potenti impact gsk
examin possibl parti reach legal settlement
trial start septemb explor rel simpl scenario
gilead pay viiv mid-single-digit mid-teen royalti us sale biktarvi
expiri dolutegravir us patent octob ignor
potenti damag award lost profit increas much
threefold estim royalti stream could worth circa
net present valu perspect tax rate wacc could add circa
gsk equiti valuat exhibit mid-point rang repres
upsid gsk equiti valuat
exhibit illustr npv calcul biktarvi royalti stream
price target base dcf use discount rate
termin growth rate model explicit product revenu bulk
gilead revenu deriv antivir product compris gilead
hepat hcv hiv franchis hcv revenu driver harvoni sovaldi epclusa
vosevi hiv product includ atripla truvada viread stribild taf-bas
regimen key non antivir product axi-cel blood cancer risk pt includ
deceler growth hcv sale volatil hiv franchis poor axi-cel launch
pipelin failur
shionogi valuat methodolog pt ep non-
discount industri average exclud takeda reflect increas
competit gilead tivicay whether shionogi maintain op growth
past hing assum global sale hiv
xofluza pt risk factor hiv slowdown delay new drug viiv
relationship acceleration/slowdown domest busi
gsk methodolog gsk underweight pt gbp pt deriv
dcf product-by-product sale forecast assum wacc
termin growth revers roce cost capit long term
valu driver hiv franchis slow increas competit
gilead vaccin shingrix consum new oncolog franchis zejula
daprodustat anemia data earli pipelin readout bcma risk
upsid consum busi return higher growth pipelin deliv
expect posit tgf-beta trap interim data readout vs keytruda risk
downsid competit pressur hiv franchis gilead mid-stag pipelin
 co plc act financi advisor
glaxosmithklin plc relat propos divest horlick consum
healthcar nutrit brand unilev plc unilev nv togeth unilev
includ merger gsk consum healthcar limit gsk india
hindustan unilev ltd glaxosmithklin plc may pay fee
financi servic pleas refer note end report
valuat methodolog risk
price target deriv dcf analysi product-by-product sale forecast
captur key patent expiri dolutegravir onward
zejula use blend wacc equiti beta termin
roce termin growth rate on-going patent litig
gilead biktarvi carri option meaning settlement windfal
risk upsid
consum busi return higher growth pipelin deliv expect
risk downsid
competit pressur hiv franchis gilead mid-stag pipelin failur
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
analyst strategist household member identifi own follow secur relat deriv thoma laveri amgen inc
common prefer stock
novemb benefici own class common equiti secur follow compani cover
within last month manag co-manag public offer offer secur abbvi inc alector inc aprea
within last month receiv compens invest bank servic abbvi inc alector inc alexion
next month expect receiv intend seek compens invest bank servic abbvi inc acceleron
within last month receiv compens product servic invest bank servic abbvi inc
within last month provid provid invest bank servic invest bank client relationship
follow compani abbvi inc alector inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani abbvi inc amgen inc astrazeneca plc bayer ag
employe director consult director merck co inc person research analyst member research
 co llc make market secur abbvi inc alector inc alexion
 co plc corpor broker astrazeneca plc hikma pharmaceut plc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
